- Home
- EXAS vs OXLCG Comparison
EXAS vs OXLCG Comparison
Compare EXAS & OXLCG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXAS
- OXLCG
- Stock Information
- Founded
- EXAS 1995
- OXLCG N/A
- Country
- EXAS United States
- OXLCG
- Employees
- EXAS N/A
- OXLCG N/A
- Industry
- EXAS Medical Specialities
- OXLCG
- Sector
- EXAS Health Care
- OXLCG
- Exchange
- EXAS Nasdaq
- OXLCG NYSE
- Market Cap
- EXAS 10.7B
- OXLCG N/A
- IPO Year
- EXAS N/A
- OXLCG N/A
- Fundamental
- Price
- EXAS $56.28
- OXLCG $24.70
- Analyst Decision
- EXAS Strong Buy
- OXLCG
- Analyst Count
- EXAS 20
- OXLCG 0
- Target Price
- EXAS $70.68
- OXLCG N/A
- AVG Volume (30 Days)
- EXAS 3.6M
- OXLCG N/A
- Earning Date
- EXAS 07-30-2025
- OXLCG N/A
- Dividend Yield
- EXAS N/A
- OXLCG N/A
- EPS Growth
- EXAS N/A
- OXLCG N/A
- EPS
- EXAS N/A
- OXLCG N/A
- Revenue
- EXAS $2,828,128,000.00
- OXLCG N/A
- Revenue This Year
- EXAS $14.58
- OXLCG N/A
- Revenue Next Year
- EXAS $12.75
- OXLCG N/A
- P/E Ratio
- EXAS N/A
- OXLCG N/A
- Revenue Growth
- EXAS 11.57
- OXLCG N/A
- 52 Week Low
- EXAS $39.97
- OXLCG N/A
- 52 Week High
- EXAS $72.83
- OXLCG N/A
- Technical
- Relative Strength Index (RSI)
- EXAS 61.48
- OXLCG N/A
- Support Level
- EXAS $55.26
- OXLCG N/A
- Resistance Level
- EXAS $58.68
- OXLCG N/A
- Average True Range (ATR)
- EXAS 1.98
- OXLCG 0.00
- MACD
- EXAS -0.14
- OXLCG 0.00
- Stochastic Oscillator
- EXAS 64.86
- OXLCG 0.00
About EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.